Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility

Our investment in domestic production with the highest quality standards will help advance patient access to high-quality cannabis. Germany’s medical cannabis market currently serves approximately 100,000 patients, representing only 0.1% of the population. State-of-the-art facility readying first delivery of medical grade cannabis for German patients EDMONTON, AB, May 18, 2022 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora“) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany. The first shipment from Aurora Leuna to German pharmacies is expected via the state’s cannabis agency later this month. The new state-of-the-art production facility in Leuna, Saxony-Anhalt, Germany adds to the company’s pan-European network of EU-GMP facilities supplying premium, high-quality cannabis flower and extracts for medical use by patients across existing and expanding markets.